Validator of a mRNA-based urine test for bladder cancer detection in patients with hematuria


Institutes: ¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²University of Nebraska Medical Center, Departments of Pathology/Microbiology, Pediatrics and Orthopaedic Surgery, Omaha, United States of America, ³Sacred Heart Hospital, Molecular Laboratory, Pensacola, United States of America, ⁴Pathology Inc., Clinical Laboratory, Torrance, United States of America, ⁵Moffitt Cancer Center, Genitourinary Oncology and Oncologic Sciences, Tampa, United States of America, ⁶University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ⁷University of Michigan Hospital, Dept. of Urology, Ann Arbor, United States of America, ⁸G. Kenneth Jansz MPC, Private Practice, Burlington, Canada, ⁹University of Tübingen, Dept. of Urology, Tübingen, Germany, ¹⁰Geisinger Health System, Dept. of Urology, Danville, United States of America, ¹¹Urological Surgeons of Long Island, PLLC, Private Practice, Garden City, United States of America, ¹²Regional Urology, Private Practice, Shreveport, United States of America, ¹³Urology of Virginia, Private Practice, Virginia Beach, United States of America, ¹⁴Kansas City Urology Care, Private Practice, Overland Park, United States of America, ¹⁵Skyline Urology, Private Practice, Torrance, United States of America, ¹⁶UroPartners, Private Practice, Melrose Park, United States of America, ¹⁷Idaho Urologic Institute, Private Practice, Meridian, United States of America, ¹⁸Virginia Urology, Private Practice, Richmond, United States of America, ¹⁹Skyline Urology, Private Practice, Sherman Oaks, United States of America, ²¹Five Valleys Urology, Private Practice, Missoula, United States of America, ²²Adult and Pediatric Urology & Urogynecology, Private Practice, Omaha, United States of America, ²³Wichita Urology Group, Private Practice, Wichita, United States of America

Does smoking influence the performance of urine markers in the diagnosis of urothelial carcinoma?

By: Schnürer S., Hennenlotter J., Dockter K., Rausch S., Stenzl A., Todenhöfer T.

Institutes: Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

Performance characteristics of a mRNA-based urine test for the detection of bladder cancer recurrence


Institutes: Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²University of Nebraska Medical Center, Dept. of Pathology/Microbiology, Pediatrics and Orthopaedic Surgery, Omaha, United States of America, ³Geisinger Health System, Dept. of Urology, Danville, United States of America, ⁴Sacred Heart Hospital, Molecular Laboratory, Pensacola, United States of America, ⁵Pathology Inc., Clinical Laboratory, Torrance, United States of America, ⁶Moffitt Cancer Center, Genitourinary Oncology and Oncologic Sciences, Tampa, United States of America, ⁷University of Michigan Hospital, Dept. of Urology, Ann Arbor, United States of America, ⁸University of Tübingen, Dept. of Urology, Tübingen, Germany, ⁹Geisinger Health System, Dept. of Urology, Danville, United States of America, ¹⁰Urological Surgeons of Long Island, PLLC, Private Practice, Garden City, United States of America, ¹¹Regional Urology, Private Practice, Shreveport, United States of America, ¹²Urology of Virginia, Private Practice, Virginia Beach, United States of America, ¹³Kansas City Urology Care, Private Practice, Overland Park, United States of America, ¹⁴Skyline Urology, Private Practice, Torrance, United States of America, ¹⁵UroPartners, Private Practice, Melrose Park, United States of America, ¹⁶Idaho Urologic Institute, Private Practice, Meridian, United States of America, ¹⁷Virginia Urology, Private Practice, Richmond, United States of America, ¹⁸Skyline Urology, Private Practice, Sherman Oaks, United States of America, ¹⁹Five Valleys Urology, Private Practice, Missoula, United States of America, ²¹Adult and Pediatric Urology & Urogynecology, Private Practice, Omaha, United States of America, ²²Wichita Urology Group, Private Practice, Wichita, United States of America
Non invasive prediction of recurrences in bladder cancer by detecting TERT promoter mutations in urine

By: Kara N.1, Descotes F.2, Decaussin Petrucci M.2, Piaton E.2, Geiguer F.2, Rodriguez-Lafrasse C.2, Terrier J.E.1, Lopez J.2, Ruffion A.1

Institutes: Centre Hospitalier Lyon-Sud, Dept. of Urology, Pierre-Bénite, France, Centre Hospitalier Lyon-Sud, Dept. of Molecular Biology and Biochemistry, Pierre-Bénite, France

Multiplex proximity extension assay of 425 candidate biomarkers in the sera of bladder cancer patients: Correlation with stage and outcome

By: Ward D.1, Gordon N.1, Abbotts B.2, James N.3, Zeegers M.4, Cheng K.K.5, Bryan R.1

Institutes: University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, University of Warwick, Clinical Trials Unit, Warwick, United Kingdom, University of Maastricht, Dept. of Complex Genetics, Birmingham, United Kingdom, University of Birmingham, School of Health and Population Sciences, Birmingham, United Kingdom

Non-invasive diagnosis and monitoring of bladder cancer utilizing high-throughput genome sequencing on urine sediment


Institutes: Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China

Method of detecting bladder cancer by optical analysis of bodily fluids

By: Rabah D.

Institutes: College of Medicine, King Saud University, Dept. of Surgery, Riyadh, Saudi Arabia

Urethral wash cytology accuracy in the diagnosis of asymptomatic urethral recurrence after radical cystectomy for urothelial bladder cancer

By: Manica M.1, Naspro R.1, Pellucchi F.1, Rocchini L.1, Roscigno M.1, Chinaglia D.2, Da Pozzo L.F.1

Institutes: Papa Giovanni Xxiii Hospital, Dept. of Urology, Bergamo, Italy, Papa Giovanni Xxiii Hospital, Dept. of Pathology, Bergamo, Italy

Diagnosis and prediction of recurrent bladder cancer by urinary DNA methylation analysis: Multicenter prospective study

By: Shindo T.1, Shimizu T.1, Nishiyama N.1, Niinuma T.2, Kitajima H.2, Kai M.2, Shinkai N.1, Itoh N.3, Tanaka T.1, Suzuki H.2, Masumori N.1

Institutes: Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, Sapporo Medical University School of Medicine, Dept. of Molecular Biology, Sapporo, Japan, NTT East Corporation Sapporo Hospital, Dept. of Urology, Sapporo, Japan

Urine-based diagnostics of bladder tumours through volatile organic compounds: A pilot study comparing two detection systems
By: Heers H.¹, Gut J.¹, Hegele A.¹, Hofmann R.¹, Boeselt T.², Hattesohl A.², Baumbach J.³, Koczulla A.R.²

Institutes: ¹Philipps-Universität Marburg, Dept. of Urology and Paediatric Urology, Marburg, Germany, ²Philipps-Universität Marburg, Dept. of Pneumology, Marburg, Germany, ³Reutlingen University, Dept. of Applied Chemistry, Reutlingen, Germany

Effect of contemporary health screening not focused on bladder cancer on diagnosis of bladder urothelial carcinoma


Institutes: Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea

Molecular tumour grading and classification of non muscle invasive bladder cancer based on whole transcriptome analysis

By: Zlotta A.R.¹, Shen J.², Noon A.³, Jiang H.⁴, Kuk C.¹, Ni R.⁵, Sukhu B.⁶, Chan K.², Erlich A.¹, Roupret M.⁶, Seisen T.⁶, Comparat E.⁷, Sweet J.⁸, Kulkarni G.S.⁹, Fleshner N.E.⁹, Azad A.⁵, Van Der Kwast T.H.¹, Wrana J.L.²

Institutes: ¹Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada, ²Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, ³University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, ⁴University Health Network, Dept. of Statistics, Toronto, Canada, ⁵Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, ⁶Groupe Hospitalier La Pitié-Salpêtrière, Université Pierre Et Marie Curie, Dept. of Urology, Paris, France, ⁷Groupe Hospitalier La Pitié-Salpêtrière, Université Pierre Et Marie Curie, Dept. of Pathology, Paris, France, ⁸Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada, ⁹Princess Margaret Cancer Centre, University Health Network, Dept. of Surgical Oncology, Urology, Toronto, Canada

Significance of serum n-glycan profiling as a diagnostic biomarker in urothelial carcinoma

By: Oikawa M.¹, Hatakeyama S.¹, Yoneyma T.², Tobisawa Y.¹, Narita T.¹, Yamamoto H.³, Hashimoto Y.², Koie T.¹, Narita S.³, Sasaki A.⁴, Tsuchiya N.⁵, Habuchi T.³, Takahashi I.⁶, Nakaji S.⁶, Ohyama C.¹

Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan, ³Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁴Tsugaru General Hospital, Dept. of Urology, Tsugaru, Japan, ⁵Yamagata University Graduate School of Medicine, Dept. of Urology, Yamagata, Japan, ⁶Hirosaki University School of Medicine, Dept. of Social Medicine, Hirosaki, Japan

Concurrent bladder tumours in patients undergoing photodynamic diagnostic ureterorenoscopy: How many lesions are missed under white light?

By: Zreik A.¹, Kata S.G.², Ahmad S.², Chlosta P.L.³, Aboumarzouk O.M.¹

Institutes: ¹Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, ²Ninewells Hospital, Dept. of Urology, Dundee, United Kingdom, ³Jagiellonian University, Dept. of Urology, Cracow, Poland

Last word on the last rite

P. Black, Vancouver (CA)